At the Fierce Pharma Engage 2026, over 600 life science directors and business development (BD&L) executives from companies like Genentech, Roche, and Sanofi gathered for highly curated, 1:1 strategic collaborations.
As a proud event sponsor, Intelligencia AI anchored the innovation floor with a dedicated corporate booth. Throughout the summit, our team met with senior leadership to demonstrate how our purpose-built machine learning ecosystems completely eliminate the historical guesswork behind high-stakes asset evaluation. By showcasing our advanced predictive tools, we showed cross-functional teams exactly how to accurately calculate an asset’s true probability of technical and regulatory success (PTRS)—empowering them to de-risk M&A due diligence and confidently navigate intense portfolio trade-offs.
High-Impact Takeaways:
- BD&L Acceleration: Leveraging objective predictive analytics to radically streamline platform-driven deals, alliance management, and asset valuation.
- The Clinical Data Edge: Overcoming tough cross-disciplinary hurdles by integrating specialized AI engines directly into clinical planning.
- Radical Portfolio Optimization: Utilizing calibrated foresight to eliminate value drain and confidently prioritize high-risk R&D pipelines.
Missed connecting with our team at the Intelligencia AI booth? Discover how we are actively removing uncertainty from the drug development lifecycle. Explore our predictive solutions portal or request a custom portfolio risk evaluation today.
